




RealRate

PHARMACEUTICAL 2021

CNBX Pharmaceuticals Inc. Rank 396 of 402





PHARMACEUTICAL 2021

CNBX Pharmaceuticals Inc.
Rank 396 of 402



The relative strengths and weaknesses of CNBX Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CNBX Pharmaceuticals Inc. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 253% points. The greatest weakness of CNBX Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 562% points.

The company's Economic Capital Ratio, given in the ranking table, is -540%, being 588% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	930
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	455
Liabilities, Non-Current	0
Other Assets	427
Other Compr. Net Income	-5,584
Other Expenses	60
Other Liabilities	0
Other Net Income	-4,424
Other Revenues	7.2
Property and Equipment	863
Research and Development	1,682
Selling, General and Administrative Expense	1,308

Output Variable	Value in 1000 USD
Assets	2,219
Liabilities	455
Expenses	3,051
Revenues	7.2
Stockholders Equity	1,765
Net Income	-7,467
Comprehensive Net Income	-10,260
Economic Capital Ratio	-540%